FOR RESEARCH USE ONLY
Predominantly preclinicalRecovery research

BPC-157

Body Protection Compound. Researched for tissue repair, gut health and connective-tissue recovery.

01Tendon & ligament02Gastrointestinal03Angiogenesis
Molecular signature / bpc-157
Structural identity

Synthetic 15-amino-acid fragment

Also known as

Body Protection Compound-157 · PL 14736

Research-use context

In-vitro and laboratory information only. No human-use recommendation.

Guide contentsOpen in calculator
Section 01

Compound briefing

BPC-157 (Body Protection Compound) is a synthetic 15-amino-acid peptide derived from a protective protein sequence found in gastric juice. Across preclinical research it has been studied extensively for cytoprotection, accelerated soft-tissue recovery, tendon-to-bone healing, and gut lining repair — with pleiotropic activity across multiple organ systems.

The research question

BPC-157 research centres on cytoprotection rather than one isolated disease target. The central question is whether its effects on nitric oxide, growth-factor signalling and cell migration can produce reproducible tissue repair beyond animal models.

Section 02

Mechanism & research themes

Acts via upregulation of the nitric oxide (NO) system, modulation of VEGF/EGF growth factor signalling, and activation of the FAK-paxillin pathway to accelerate fibroblast migration and tissue remodelling. Demonstrates both peripheral and central activity.

01

Studied for accelerated tendon, ligament and muscle repair

02

Researched for gastric ulcer and IBD-model gut healing

03

Neuroprotection and recovery in TBI animal models

04

Suppression of NF-κB and pro-inflammatory cytokines

05

Enhanced callus formation in fracture-repair research

06

Cytoprotective effects across multiple organ systems

These are research themes reported across the literature, not established benefits or indications.

Section 03

Evidence assessment

Predominantly preclinical

The literature is dominated by rodent and cell studies. Human pharmacokinetic and controlled efficacy data remain insufficient for firm clinical conclusions.

What to look for

Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.

What not to assume

A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.

Section 04

Protocol literature

Commonly referenced research protocols use 200–500mcg per day subcutaneously (approximately 2–10mcg/kg), administered once or twice daily, in 4–12 week cycles. 8 weeks on / 4 weeks off is a frequently cited schedule.

Reported persistence

approximately 4 hours (animal pharmacokinetic estimates; human PK data remains limited)

Calculator starting point

0.3 mg per reference dose

7 doses per week · 8-week cycle

2 mL default reconstitution volume

Typical research range 200–500 mcg/day SC for 4–12 weeks.

Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.

Calculate BPC-157
Section 05

Laboratory handling

Reconstitution reference

Reconstitute a 5mg vial with 2mL of bacteriostatic water, injected slowly down the side of the vial, for a 2.5mg/mL (2,500mcg/mL) working concentration. Swirl gently — do not shake.

Storage reference

Lyophilised: refrigerate at 2–8°C (stable up to approximately 24 months); avoid freeze-thaw cycles. Reconstituted: store at 2–8°C, protect from light, and use within 30 days.

Minimum documentation standard

  • Record the lot identifier and review its matching analytical documentation.
  • Use aseptic technique and record diluent, final volume and calculated concentration.
  • Label preparation date, storage conditions and any light or freeze–thaw restrictions.
  • Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Section 06

Limitations & safety

L1

Theoretical VEGF/angiogenesis concern noted in 2025 reviews — precautionary for subjects with pre-existing neoplastic tissue.

L2

Efficacy data is primarily preclinical (rodent); no completed human RCTs as of mid-2025.

L3

Mild nausea has been reported anecdotally at higher doses; tolerability is otherwise considered favourable in animal research.

Research use only

This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.

Continue reading

Related field notes

Back to all field notes

Welcome to HV Labs

Please confirm your age to continue.

For research use only